284 related articles for article (PubMed ID: 22178517)
41. B subunit of Escherichia coli heat-labile enterotoxin as adjuvant of humoral immune response in recombinant BCG vaccination.
da Silva Ramos Rocha A; Conceição FR; Grassmann AA; Lagranha VL; Dellagostin OA
Can J Microbiol; 2008 Aug; 54(8):677-86. PubMed ID: 18772930
[TBL] [Abstract][Full Text] [Related]
42. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.
Arrington J; Braun RP; Dong L; Fuller DH; Macklin MD; Umlauf SW; Wagner SJ; Wu MS; Payne LG; Haynes JR
J Virol; 2002 May; 76(9):4536-46. PubMed ID: 11932419
[TBL] [Abstract][Full Text] [Related]
43. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
[TBL] [Abstract][Full Text] [Related]
44. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
[TBL] [Abstract][Full Text] [Related]
45. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.
Yu J; Cassels F; Scharton-Kersten T; Hammond SA; Hartman A; Angov E; Corthésy B; Alving C; Glenn G
Infect Immun; 2002 Mar; 70(3):1056-68. PubMed ID: 11854183
[TBL] [Abstract][Full Text] [Related]
46. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
McCluskie MJ; Weeratna RD; Clements JD; Davis HL
Vaccine; 2001 Jun; 19(27):3759-68. PubMed ID: 11395211
[TBL] [Abstract][Full Text] [Related]
47. Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with E. coli heat labile enterotoxin B subunit.
Wan J; Wang T; Xu J; Ouyang T; Wang Q; Zhang Y; Weng S; Li Y; Wang Y; Xin X; Wang X; Li S; Kong L
EBioMedicine; 2021 May; 67():103353. PubMed ID: 33971403
[TBL] [Abstract][Full Text] [Related]
48. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM
Vaccine; 2014 Dec; 32(52):7077-84. PubMed ID: 25444830
[TBL] [Abstract][Full Text] [Related]
49. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
[TBL] [Abstract][Full Text] [Related]
50. Toxicity and immunogenicity of Enterotoxigenic Escherichia coli heat-labile and heat-stable toxoid fusion 3xSTa(A14Q)-LT(S63K/R192G/L211A) in a murine model.
Zhang C; Knudsen DE; Liu M; Robertson DC; Zhang W;
PLoS One; 2013; 8(10):e77386. PubMed ID: 24146989
[TBL] [Abstract][Full Text] [Related]
51. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection.
Weltzin R; Guy B; Thomas WD; Giannasca PJ; Monath TP
Infect Immun; 2000 May; 68(5):2775-82. PubMed ID: 10768972
[TBL] [Abstract][Full Text] [Related]
52. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.
Douce G; Giannelli V; Pizza M; Lewis D; Everest P; Rappuoli R; Dougan G
Infect Immun; 1999 Sep; 67(9):4400-6. PubMed ID: 10456880
[TBL] [Abstract][Full Text] [Related]
53. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells.
Guebre-Xabier M; Hammond SA; Epperson DE; Yu J; Ellingsworth L; Glenn GM
J Virol; 2003 May; 77(9):5218-25. PubMed ID: 12692224
[TBL] [Abstract][Full Text] [Related]
54. Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III.
Chiang CY; Huang MH; Pan CH; Hsieh CH; Chen MY; Liu HH; Tsai JP; Liu SJ; Chong P; Leng CH; Chen HW
Microbes Infect; 2013; 15(10-11):719-28. PubMed ID: 23774693
[TBL] [Abstract][Full Text] [Related]
55. Parenteral adjuvant potential of recombinant B subunit of Escherichia coli heat-labile enterotoxin.
Cunha CEPD; Moreira C; Rocha ADSR; Finger PF; Magalhães CG; Ferreira MRA; Dellagostin OA; Moreira ÂN; Conceição FR
Mem Inst Oswaldo Cruz; 2017 Dec; 112(12):812-816. PubMed ID: 29211241
[TBL] [Abstract][Full Text] [Related]
56. Modified heat-stable toxins (hSTa) of enterotoxigenic Escherichia coli lose toxicity but display antigenicity after being genetically fused to heat-labile toxoid LT(R192G).
Liu M; Zhang C; Mateo K; Nataro JP; Robertson DC; Zhang W
Toxins (Basel); 2011 Sep; 3(9):1146-62. PubMed ID: 22069760
[TBL] [Abstract][Full Text] [Related]
57. Intranasal immunization with live recombinant Lactococcus lactis combined with heat-labile toxin B subunit protects chickens from highly pathogenic avian influenza H5N1 virus.
Lei H; Peng X; Shu H; Zhao D
J Med Virol; 2015 Jan; 87(1):39-44. PubMed ID: 24861477
[TBL] [Abstract][Full Text] [Related]
58. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399
[TBL] [Abstract][Full Text] [Related]
59. Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities.
Nawar HF; Arce S; Russell MW; Connell TD
Infect Immun; 2005 Mar; 73(3):1330-42. PubMed ID: 15731030
[TBL] [Abstract][Full Text] [Related]
60. Development of a Bacillus subtilis-based rotavirus vaccine.
Lee S; Belitsky BR; Brinker JP; Kerstein KO; Brown DW; Clements JD; Keusch GT; Tzipori S; Sonenshein AL; Herrmann JE
Clin Vaccine Immunol; 2010 Nov; 17(11):1647-55. PubMed ID: 20810679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
